Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;8(2):185-194.
doi: 10.1177/2050640619882157. Epub 2019 Oct 3.

Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme

Wessel van de Veerdonk  1 , Sarah Hoeck  1   2 , Marc Peeters  3   4 , Guido Van Hal  1   2 , Julie Francart  5 , Isabel De Brabander  5
Affiliations

Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme

Wessel van de Veerdonk et al. United European Gastroenterol J. 2020 Mar.

Abstract

Background: Colorectal cancer (CRC) and its precursor lesions are detected at an early stage by CRC screening programmes, which reduce CRC-related mortality. An important quality indicator for CRC screening is the occurrence of interval CRC (IC) between screening rounds. Currently there is no guideline regarding acceptable levels of ICs in CRC screening programmes, and ICs reported in prior work vary considerably.

Methods: This study describes the occurrence of screen-detected (SD) CRC and non-screen-detected CRC within the population-based CRC screening programme of Flanders, stratified by multiple variables such as sex, age, tumour location and tumour stage between October 2013 and July 2017. In addition, faecal immunochemical test (FIT) IC proportions over the sum of SD-CRCs and FIT-ICs are calculated, together with FIT sensitivity and programme sensitivity to display the effectiveness of detecting CRC by the screening programme.

Results: Of 1,212,354 FIT participants, 4094 were diagnosed with SD-CRC, whereas 772 participants were diagnosed with CRC between FIT-screening rounds. Significant associations were shown between people not being SD for CRC and women, older individuals, right-sided tumour location and more advanced tumour stage. Furthermore, a clear distinction was shown between the right-sided and the left-sided colorectum concerning all above-mentioned variables and distributions of tumour stages.

Conclusion: The Flemish FIT-interval CRC proportion of 15.9% was within the limits of previously published results. In addition, calculations show that the effectiveness of the screening programme is dependent on tumour location, suggesting that future research should report results stratified by location.

Keywords: Colorectal cancer screening; FIT; interval cancers; non–screen-detected colorectal cancers.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the Flemish CRC screening programme and FIT non-participant outcomes between October 2013 and July 2017 with screen-detected and non–screen-detected CRCs. (a) Exclusion from screening applies if people are screened by either a FIT or gFOBT two years prior to invitation, had a colectomy in the past, or a colonoscopy or CRC diagnosis in the last 10 years. (b) No follow-up performed or another follow-up procedure performed such as another FIT, other imaging, surgery, or virtual colonoscopy. CRC: colorectal cancer; FIT: faecal immunochemical test; gFOBT: guaiac faecal occult blood test; Y-Avg.: yearly average.
Figure 2.
Figure 2.
Time from faecal immunochemical test (FIT) participation to colorectal cancer (CRC) diagnosis. The Y-axis is free in this figure and needs to be taken into account for interpretation.
Figure 3.
Figure 3.
Distribution of CRC stage according to the different categories and tumour location from 2013 to 2015. CRC: colorectal cancer; cTNM: clinical tumour-node-metastasis staging; FIT: faecal immunochemical test; IC: interval cancer; pTNM: pathological tumour-node-metastasis staging.
Figure 4.
Figure 4.
Calculations of colorectal cancer (CRC) screening programme sensitivity, faecal immunochemical test (FIT) sensitivity and FIT interval cancer (IC) proportions, according to carcinoma in situ or CRC and tumour location. These calculations are based on data from 2013 until 2015 for valid calculation due to complete data on interval cancers.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. - PubMed
    1. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: A global overview of existing programmes. Gut 2015; 64: 1637–1649. - PubMed
    1. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472–1477. - PubMed
    1. Hoeck S, Pringels S, Kellen E, et al. First results of the Flemish colorectal cancer screening program: Start-up- period late 2013. Acta Gastroenterol Belg 2016; 79: 421–428. - PubMed
    1. The Centre for Cancer Detection and The Belgian Cancer Registry. Monitoring report of the Flemish Colorectal Cancer Screening Programme, https://dikkedarmkanker.bevolkingsonderzoek.be/sites/default/files/atoms... (2017, accessed 4 January 2019).